| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| Gene symbol | MS4A1 | Synonyms | B1, Bp35, CD20, CVID5, FMC7, LEU-16, S7 | Type of gene | protein-coding |
| Chromosome | 11 | Map location | 11q12.2 | dbXrefs | |
| Description | membrane spanning 4-domains A1 | ||||
| GTO ID | GTC0494 |
| Trial ID | NCT04007029 |
| Disease | Mantle Cell Lymphoma | Small Lymphocytic Lymphoma | Chronic Lymphocytic Leukemia | Diffuse Large B-Cell Lymphoma | Follicular Lymphoma | Lymphoplasmacytic Lymphoma | Primary Mediastinal B-Cell Lymphoma |
| Altered gene | CD19|CD20 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | CD19/CD20 CAR-T cells |
| Generation | 2nd |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia |
| Year | 2019 |
| Country | United States |
| Company sponsor | Jonsson Comprehensive Cancer Center |
| Other ID(s) | 18-001989|NCI-2019-03190|18-001989 |
| Vector information | |||||||||
|
|||||||||
| Cohort 1 | |||||||||||||||||||
|
|||||||||||||||||||